Sep 3, 2026 —
Typewriter Therapeutics has emerged from stealth with $56 million in Series A financing to advance its non-viral, in vivo gene therapy platform toward the clinic. The round was led by RA Capital Management and AN Venture Partners.
The company’s platform uses target-primed reverse transcription (TPRT) to insert therapeutic genetic sequences directly in vivo without viral vectors. Typewriter describes the RNA-based, lipid-nanoparticle-delivered system as re-dosable and is initially focusing on in vivo CAR-T and hereditary liver diseases.
The financing will support development of the platform toward first clinical testing.
